Efficacy and Safety of CKD-501 Added to D150 Plus D745 10mg Therapy in Patients With Type 2 Diabetes
Status:
Completed
Trial end date:
2020-12-02
Target enrollment:
Participant gender:
Summary
The purpose of this study is to prove that the group treated with CKD-501 in combination
added that the reduction of glycated hemoglobin superior to placebo treated group added in
combination.